Breakthrough Research at EADV 2025 Shows GLP-1RAs Significantly Lower Cardiovascular Risks in Psoriasis Patients Recent findings from EADV 2025 reveal that GLP-1 receptor agonists significantly reduce cardiovascular risks and mortality in psoriasis patients.

Breakthrough Research at EADV 2025 Shows GLP-1RAs Significantly Lower Cardiovascular Risks in Psoriasis Patients #None #Paris #Psoriasis #EADV_Congress #GLP-1RAs

Atopic Eczema and Suicidal Thoughts: New Findings from EADV Congress 2025 Recent research at the EADV Congress 2025 links atopic eczema to increased risks of suicidal thoughts, emphasizing the mental health challenges faced by those affected.

Atopic Eczema and Suicidal Thoughts: New Findings from EADV Congress 2025 #USA #Paris #EADV_Congress #Atopic_Eczema #Suicidal_Ideation

Innovent to Showcase Cutting-Edge Biomedicine Research Results at EADV 2025 Congress Innovent Biologics will present significant findings on innovative biomedicine treatments during the 34th EADV Congress in Paris, highlighting progress in various disease areas.

Innovent to Showcase Cutting-Edge Biomedicine Research Results at EADV 2025 Congress #Suzhou #Innovent_Biologics #EADV_Congress #IL-23p19

Nektar's Exciting Phase 2b Results for Rezpegaldesleukin to be Presented at EADV 2025 Congress Nektar Therapeutics is set to reveal key findings from the REZOLVE-AD Phase 2b study of Rezpegaldesleukin at the upcoming EADV 2025 Congress in Paris, showcasing its potential in treating atopic dermatitis.

Nektar's Exciting Phase 2b Results for Rezpegaldesleukin to be Presented at EADV 2025 Congress #United_States #San_Francisco #Nektar_Therapeutics #Rezpegaldesleukin #EADV_Congress